Get the Stockscreener App
23.99
0.14%
0.0775
Schrodinger Inc stock is traded at $23.99, with a volume of 386.42K.
It is up +0.14% in the last 24 hours and down -2.23% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$23.91
Open:
$24.02
24h Volume:
386.42K
Relative Volume:
0.34
Market Cap:
$1.91B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-9.7908
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
-7.84%
1M Performance:
-2.23%
6M Performance:
+7.61%
1Y Performance:
+5.34%
1-Day Range:
$23.50
$24.66
1-Week Range:
$22.69
$25.54
52-Week Range:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
24.00 | 1.91B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
236.82 | 38.62B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.98 | 11.14B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
64.27 | 9.36B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
95.27 | 7.91B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
40.26 | 7.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrödinger, Inc. (NASDAQ:SDGR) Q1 2025 Earnings Call Transcript - Insider Monkey
Schrödinger First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Schrödinger, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic ... - Yahoo Finance
Schrodinger Inc (SDGR) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Strategic Advancements - GuruFocus
Decoding Schrodinger Inc (SDGR): A Strategic SWOT Insight - GuruFocus
Schrödinger Q1 2025 slides: revenue jumps 63%, clinical readouts on horizon - Investing.com Canada
Schrödinger projects strong 2025 revenue growth with $45M-$50M in drug discovery - MSN
Schrodinger Inc (SDGR) Q1 2025 Earnings: Revenue Surges to $59.6M, Beating Estimates; Net Loss Widens to $59.8M - GuruFocus
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Schrodinger Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Schrodinger Q1 2025 beats EPS expectations, stock rises - Investing.com
Schrodinger (SDGR) Surpasses Revenue Expectations with Strong Gr - GuruFocus
Schrodinger (SDGR) Reaffirms 2025 Financial Projections | SDGR Stock News - GuruFocus
Earnings Flash (SDGR) SCHRODINGER Reports Q1 Revenue $59.6M, vs. FactSet Est of $54.7M - marketscreener.com
Schrodinger earnings beat by $0.10, revenue topped estimates - Investing.com
Schrödinger Reports Strong First Quarter 2025 Financial Results - Eagle-Tribune
Is Now An Opportune Moment To Examine Schrödinger, Inc. (NASDAQ:SDGR)? - Yahoo Finance
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - Benzinga
Schrödinger to Present at BofA Securities 2025 Healthcare Conference - 01net
Schrödinger to Present at BofA Securities 2025 Healthcare Conference | SDGR Stock News - GuruFocus
Learn to Evaluate (SDGR) using the Charts - news.stocktradersdaily.com
Top 5 AI & Digital Biotech Companies (May 2025) - Securities.io
Schrödinger Demonstrates Corporate Sustainability Progress in 2024 Report - ReportAlert
Schrodinger Inc (SDGR) Shares Gap Down to $25.585 on Apr 28 - GuruFocus
Schrödinger, Inc. (NASDAQ:SDGR) Looks Just Right With A 33% Price Jump - simplywall.st
Schrödinger Presents New Preclinical Data at AACR Annual Meeting - 01net
Schrödinger, Inc. (SDGR): Among Top Stocks in Bill Gates’ Portfolio with Huge Upside Potential - Insider Monkey
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 | SDGR Stock News - GuruFocus
Schrödinger to Announce First Quarter 2025 Financial Results on May 7 - marketscreener.com
3 Momentum Stocks That Could Soar Post-Market Volatility - MarketBeat
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - 01net
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | SDGR Stock News - GuruFocus
Schrödinger (NASDAQ:SDGR) shareholders are up 29% this past week, but still in the red over the last five years - simplywall.st
Schrodinger (SDGR) Moves 27.4% Higher: Will This Strength Last? - MSN
An Intrinsic Calculation For Schrödinger, Inc. (NASDAQ:SDGR) Suggests It's 26% Undervalued - Yahoo Finance
Schrodinger price target raised to $32 from $30 at KeyBanc - TipRanks
Schrodinger’s Karen Akinsanya sells $419,570 in stock By Investing.com - Investing.com South Africa
Schrodinger’s Karen Akinsanya sells $419,570 in stock - Investing.com
Schrodinger issues statement on FDA phasing out animal testing requirement - TipRanks
FDA recent move marks paradigm shift in drug development, boosting Schrödinger (SDGR) and other biotech stocks - Investorsobserver
Schrodinger (SDGR) Backs FDA's Initiative to Cut Animal Testing in Drug Development | SDGR Stock News - GuruFocus
Schrödinger's Statement Regarding FDA Plan to Phase Out Animal T - GuruFocus
Schrödinger backs FDA’s move away from animal testing By Investing.com - Investing.com South Africa
Schrodinger to Launch Predictive Toxicology Tool in H2 - marketscreener.com
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs - 01net
Schrödinger backs FDA’s move away from animal testing - Investing.com Australia
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Schrodinger Inc Stock (SDGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
0.21%
3.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):